NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics, Inc. (NASDAQ:IMMU) announced its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biopharmaceutical company earned $0.50 million during the quarter, compared to analyst estimates of $4.27 million. Immunomedics's quarterly revenue was down 61.5% compared to the same quarter last year. View Immunomedics' Earnings History.

4 Wall Street analysts have issued 12 month target prices for Immunomedics' shares. Their forecasts range from $15.00 to $53.00. On average, they anticipate Immunomedics' share price to reach $31.50 in the next year. View Analyst Ratings for Immunomedics.

Immunomedics saw a decrease in short interest during the month of May. As of May 31st, there was short interest totalling 27,938,918 shares, a decrease of 7.9% from the May 15th total of 30,336,254 shares. Based on an average trading volume of 2,772,728 shares, the short-interest ratio is presently 10.1 days. Approximately 19.3% of the company's shares are short sold. View Immunomedics' Current Options Chain.

Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Intellia Therapeutics (NTLA), Meridian Bioscience (VIVO), Lantheus (LNTH), Quotient (QTNT), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Riot Blockchain (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML) and ImmuCell (ICCC).

Headlines about IMMU stock have trended positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immunomedics earned a news impact score of 0.33 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Immunomedics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.45%), SEATTLE GENETICS INC (4.90%), Acuta Capital Partners LLC (3.50%), Palo Alto Investors LP (2.87%), Victory Capital Management Inc. (1.13%) and Northern Trust Corp (0.76%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg, Don C Stark, Mary E Paetzold and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

IMMU stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, JPMorgan Chase & Co., Lyon Street Capital LLC, UBS Group AG, Jane Street Group LLC, Iguana Healthcare Management LLC, Highland Capital Management LP and BlackRock Inc.. Company insiders that have sold Immunomedics company stock in the last year include Brian A Markison, Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

IMMU stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Nexthera Capital LP, Massachusetts Financial Services Co. MA, Rock Springs Capital Management LP, Sphera Funds Management LTD., University of Notre Dame DU Lac, Royal Bank of Canada and DekaBank Deutsche Girozentrale. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $24.36.

Immunomedics has a market capitalization of $4.24 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]